


# Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2020 BPCA Stakeholders Meeting Evaluation

OMB # 0925-0648

Expiration Date: 5/2021

Public reporting burden for this collection of information is estimated to average 5-10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

**Thank you for attending the 2020 BPCA Stakeholders Meeting! Please take 5-10 minutes to evaluate this meeting. Our goal is to obtain feedback so that we can improve the next meeting.**

**Select the primary reasons for your participation in the 2020 BPCA Stakeholders Meeting.**

- Interest in the Best Pharmaceuticals for Children Act
- Interest in collaborating with the Pediatric Trials Network
- Former member of a therapeutic area working group
- Other (please specify)

**How did you learn about the 2020 BPCA Annual Meeting?**

- Best Pharmaceuticals for Children Act updates (emails from [bpc@infinityconferences.com](mailto:bpc@infinityconferences.com))
- U.S. Food and Drug Administration updates
- Word of mouth
- Other (please specify)

[Redacted text]

**Please provide your feedback regarding the virtual format of this meeting.**

[Redacted text]

**Please provide your feedback regarding the content of the meeting.**

[Redacted text]

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute of Child Health and Human Development



## 2020 BPCA Stakeholders Meeting Evaluation

### MEETING CONTENT

On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the following sessions:

**Triumphs and Trials in Pediatric Therapeutics – Perspectives from the Pediatric Trials Network and EMMES Data Coordinating Center (Benjamin/Zimmerman/Anand)**

1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Additional Comments

**Regulatory Considerations for Addressing Needs in Pediatric Therapeutics (Alexander/Burckart)**

1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Additional Comments

## The COVID-19 Pandemic: Pediatric Therapeutics, Lessons Learned, and Impact on Future Directions in Pediatrics Research (Hazra)

1

2

3

4

5

Additional Comments

## NICHD Strategic Planning Overview (Cernich)

1

2

3

4


5

Additional Comments

Please provide your feedback regarding the roundtable discussion/breakout sessions on December 15.

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2020 BPCA Stakeholders Meeting Evaluation

### GENERAL FEEDBACK


On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” what is your overall rating of the meeting?


1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

How can we improve the next BPCA Stakeholders Meeting?

What aspects of the 2020 BPCA Stakeholders Meeting were most useful to you?

# Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2020 BPCA Stakeholders Meeting Evaluation

### FUTURE ACTIVITIES

If you are not on the BPCA Stakeholders mailing list, would you like to be added?

Yes

No

Would you like to participate in a BPCA Focus Group in 2021?

Yes

No

If yes, please indicate your preferred area of interest.

Advancing Clinical Trial Design

Biomarkers Research

PK Modeling that Informs Dosing

Pediatric-Friendly Formulations


Pharmacoepidemiology Studies

Systems Pharmacology

# Best Pharmaceuticals for Children Act



Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2020 BPCA Stakeholders Meeting Evaluation

### CONTACT DETAILS - OPTIONAL

If you would like a response to your feedback, to join a BPCA working group, or to be added to the BPCA Stakeholders distribution list, please be sure to include your contact information below:

Name

Email Address

Phone